We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+3.91%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$245M
AUM Growth
+$31M
Cap. Flow
+$33M
Cap. Flow %
13.48%
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49

Top Buys

Rank Stock Value
1
JNK icon
State Street SPDR Bloomberg High Yield Bond ETF
JNK
+$1.9M
2
COIN icon
Coinbase
COIN
+$1.35M
3
DOCU
DocuSign
DOCU
+$1.32M
4
SPOT icon
Spotify
SPOT
+$1.28M
5
UAL icon
United Airlines
UAL
+$1.28M

Top Sells

Rank Stock Value
1
APP icon
Applovin
APP
+$1.14M
2
EXPE icon
Expedia Group
EXPE
+$1.04M
3
KKR icon
KKR & Co
KKR
+$976K
4
CME icon
CME Group
CME
+$974K
5
CPAY icon
Corpay
CPAY
+$948K

Sector Composition

Rank Sector Weight
1 Financials 29.48%
2 Technology 14.86%
3 Healthcare 14.81%
4 Industrials 11.61%
5 Consumer Discretionary 6.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIR icon
376
Vir Biotechnology
VIR
$1.44B
$70.2K 0.03%
9,568
+674
+8% +$5.32K
IRON icon
377
Disc Medicine
IRON
$2.8B
$70.1K 0.03%
1,106
-1,247
-53% -$72.1K
SNDX icon
378
Syndax Pharmaceuticals
SNDX
$1.69B
$69.8K 0.03%
5,278
+827
+19% +$14.2K
ELVN icon
379
Enliven Therapeutics
ELVN
$3.76B
$69.5K 0.03%
3,091
-1,097
-26% -$28.4K
RVMD icon
380
Revolution Medicines
RVMD
$38.2B
$69.2K 0.03%
1,582
-739
-32% -$37.3K
SYRE icon
381
Spyre Therapeutics
SYRE
$8.34B
$69.2K 0.03%
2,972
+124
+4% +$3.64K
SLNO
382
DELISTED
Soleno Therapeutics
SLNO
$69K 0.03%
1,536
-514
-25% -$26.6K
ARVN icon
383
Arvinas
ARVN
$526M
$69K 0.03%
3,601
+115
+3% +$2.79K
PRME icon
384
Prime Medicine
PRME
$538M
$69K 0.03%
23,618
+11,948
+102% +$41.9K
RXRX icon
385
Recursion Pharmaceuticals
RXRX
$1.58B
$68.9K 0.03%
10,185
+422
+4% +$2.84K
ZNTL icon
386
Zentalis Pharmaceuticals
ZNTL
$325M
$68.8K 0.03%
22,713
+13,030
+135% +$42.7K
ARCT icon
387
Arcturus Therapeutics
ARCT
$160M
$68.7K 0.03%
4,051
+1,132
+39% +$21.3K
ITOS
388
DELISTED
iTeos Therapeutics
ITOS
$68.7K 0.03%
8,948
+3,293
+58% +$28.3K
BCAX
389
Bicara Therapeutics
BCAX
$1.72B
$68.6K 0.03%
+3,939
New +$82K
CRGX
390
DELISTED
CARGO Therapeutics
CRGX
$68.6K 0.03%
4,758
-610
-11% -$11.1K
CAPR icon
391
Capricor Therapeutics
CAPR
$380M
$68.4K 0.03%
+4,957
New +$86.9K
IMTX icon
392
Immatics
IMTX
$1.18B
$68.2K 0.03%
9,594
+2,479
+35% +$21.3K
AKRO
393
DELISTED
Akero Therapeutics
AKRO
$68.1K 0.03%
2,449
-1,292
-35% -$39.1K
ORIC icon
394
Oric Pharmaceuticals
ORIC
$1.17B
$68.1K 0.03%
8,434
-3,563
-30% -$32.7K
PTGX icon
395
Protagonist Therapeutics
PTGX
$8.72B
$68K 0.03%
1,761
-919
-34% -$40.1K
CLDX icon
396
Celldex Therapeutics
CLDX
$2.81B
$67.9K 0.03%
2,688
+159
+6% +$4.32K
ERAS icon
397
Erasca
ERAS
$6.01B
$67.8K 0.03%
27,031
-15,244
-36% -$41.8K
TRDA icon
398
Entrada Therapeutics
TRDA
$242M
$67.8K 0.03%
+3,924
New +$71.1K
KYMR icon
399
Kymera Therapeutics
KYMR
$8.69B
$67.8K 0.03%
1,686
-954
-36% -$43.1K
PLRX icon
400
Pliant Therapeutics
PLRX
$66.3M
$67.6K 0.03%
5,133
-2,564
-33% -$35K
14 15
16
17 18

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2024 Portfolio in Review

As of Q4 2024, Virtus ETF Advisers held 511 positions worth $245M, up 15% from $214M the previous quarter. Its ten largest holdings account for 7.3% of the portfolio.

Virtus ETF Advisers deployed $33M of net new capital in Q4 2024, opening 57 new positions and adding to 251 existing holdings. Its largest new stake was State Street SPDR Bloomberg High Yield Bond ETF: 19,660 shares worth $1.88M.

By sector, the portfolio is most concentrated in Financials at 29% of assets, up from 28% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Applovin, an estimated $1.14M trimmed.

  • Virtus ETF Advisers's largest Q4 2024 buy was State Street SPDR Bloomberg High Yield Bond ETF: 19,660 shares worth $1.88M.
  • Virtus ETF Advisers added most to Eagle Point Credit Company in Q4 2024, an estimated $515K increase.
  • Virtus ETF Advisers's biggest Q4 2024 reduction was Applovin, cutting an estimated $1.14M.
  • Virtus ETF Advisers fully exited Expedia Group in Q4 2024, selling an estimated $1.04M.
  • Virtus ETF Advisers's ten largest holdings make up 7.3% of its $245M portfolio in Q4 2024.
  • Virtus ETF Advisers opened 57 new positions and closed 49 in Q4 2024.
  • Virtus ETF Advisers's portfolio value rose 15% quarter-over-quarter to $245M.

Based on Virtus ETF Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.